A5063804971- RNA Interference and Gene Delivery
- Advanced biosensing and bioanalysis techniques
- Phagocytosis and Immune Regulation
- Cancer Mechanisms and Therapy
- PI3K/AKT/mTOR signaling in cancer
- Cancer Genomics and Diagnostics
- Mechanisms of cancer metastasis
- Nuclear Receptors and Signaling
- Microtubule and mitosis dynamics
- Monoclonal and Polyclonal Antibodies Research
- Pancreatic and Hepatic Oncology Research
- CAR-T cell therapy research
- Bioinformatics and Genomic Networks
- Nanoparticle-Based Drug Delivery
- Gene expression and cancer classification
- Graphene and Nanomaterials Applications
- Caveolin-1 and cellular processes
- Cancer therapeutics and mechanisms
- Pancreatic function and diabetes
- Nanofabrication and Lithography Techniques
- HER2/EGFR in Cancer Research
- DNA Repair Mechanisms
- Estrogen and related hormone effects
- Genomics and Chromatin Dynamics
- Advanced Nanomaterials in Catalysis
Atara Biotherapeutics (United States)
2020-2025
Oregon Health & Science University
2012-2019
University of Portland
2013
McGill University
2012
Peter MacCallum Cancer Centre
2012
The University of Texas MD Anderson Cancer Center
2012
Lawrence Berkeley National Laboratory
2008-2011
GlaxoSmithKline (United States)
2008
KRAS mutation is a hallmark of pancreatic ductal adenocarcinoma (PDA) but remains an intractable pharmacologic target. Consequently, defining RAS effector pathway(s) required for PDA initiation and maintenance critical to improve treatment this disease. Here, we show that expression BRAF(V600E), not PIK3CA(H1047R), in the mouse pancreas leads intraepithelial neoplasia (PanIN) lesions. Moreover, concomitant BRAF(V600E) TP53(R270H) result lethal PDA. We tested inhibitors effectors against...
In vivo delivery of siRNAs designed to inhibit genes important in cancer and other diseases continues be an biomedical goal. A new nanoparticle construct that is engineered for efficient siRNA tumors now described. The comprises a 47‐nm mesoporous silica core coated with crosslinked polyethyleneimine–polyethyleneglycol copolymer, carrying against the human epidermal growth factor receptor type 2 (HER2) oncogene, coupled anti‐HER2 monoclonal antibody (trastuzumab). increase blood half‐life,...
Abstract Introduction HJURP (Holliday Junction Recognition Protein) is a newly discovered gene reported to function at centromeres and interact with CENPA. However its role in tumor development remains largely unknown. The goal of this study was investigate the clinical significance breast cancer correlation radiotherapeutic outcome. Methods We measured expression level human cell lines primary cancers by Western blot and/or Affymetrix Microarray; determined associations variables using...
Long-term stability of therapeutic candidates is necessary toward their clinical applications. For most nanoparticle systems formulated in aqueous solutions, lyophilization or freeze-drying a common method to ensure long-term stability. While lipid, polymeric, inorganic nanoparticles have been studied, little has reported on and hybrid systems, consisting polymers, particles, antibody. Lyophilization complex can be challenging with respect preserving physicochemical properties the biological...
Abstract Metastatic breast cancer is developed in about 20% to 30% of newly diagnosed patients with early-stage despite treatments. Herein, we report a novel nanoparticle platform intrinsic antimetastatic properties for the targeted delivery Polo-like kinase 1 siRNA (siPLK1). We first evaluated it triple-negative (TNBC) model, which shows high metastatic potential. PLK1 was identified as top therapeutic target TNBC cells and tumor-initiating kinome-wide screen. The consists 50-nm mesoporous...
// Shenda Gu 1, * , Zhi Hu Worapol Ngamcherdtrakul 2 David J. Castro Jingga Morry 1 Moataz M. Reda Joe W. Gray Wassana Yantasee Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, 97239, USA PDX Pharmaceuticals, LLC, These authors have contributed equally to this work Correspondence to: Gray, e-mail: grayjo@ohsu.edu Yantasee, yantasee@ohsu.edu Keywords: siRNA, HER2, trastuzumab resistance, breast cancer, nanoparticles Received: December 17,...
Prostate cancer is a leading cause of cancer-related mortality in men, highlighting the resistance to current treatments and need for new therapeutic options. PSMA (Prostate-Specific Membrane Antigen) overexpressed prostate tissues compared normal prostatic tissue, rendering it an ideal target therapies, enabling precise delivery agents cells. We evaluated expression 77 Chinese patients using immunohistochemistry (IHC), confirming its high malignant tissues. Due lack clinical activity from T...
Abstract Effective targeting of solid tumors using T cell engagers remains challenging due to the lack tumor specific antigens (TSA), and difficulty in achieving sustained anti-tumor response. Frequently, target antigen expression is upregulated on cancer, yet low normal tissues limits therapeutic window. Moreover, co-stimulatory signals paired with CD3 microenvironment often leads exhaustion non-durable responses. To overcome these shortcomings, we have developed a tetraspecific engaging...
Intrinsic and acquired resistance to current HER2 targeted therapies remains a challenge in clinics. We have developed therapeutic siRNA delivered using mesoporous silica nanoparticles modified with polymers conjugated targeting antibodies. Our previous studies shown that our could overcome intrinsic trastuzumab lapatinib HER2-positive breast cancers. In this study, we investigated the effect of long-term (7 months) treatment siRNA. Even after removal siRNA, treated cells grew much slower...
High mitotic activity is associated with the genesis and progression of many cancers. Small molecule inhibitors apparatus proteins are now being developed evaluated clinically as anticancer agents. With clinical trials several these experimental compounds underway, it important to understand molecular mechanisms that determine high activity, identify tumor subtypes carry aberrations confer develop markers distinguish which tumors will be most responsive inhibitors. We identified a...
Multiparametric and high-content protein analysis of single cells or tissues cannot be accomplished with the currently available flow cytometry imaging techniques utilizing fluorophore-labelled antibodies, because number spectrally resolvable fluorochromes is limited. In contrast, mass can resolve more signals by exploiting lanthanide-tagged antibodies; however, only about 100 metal reporters attached to an antibody molecule. This makes sensitivity antibodies substantially lower than...
The front cover illustrates nanoparticle-assisted delivery of siRNA to tumor cells upon systemic administration. After circulating in blood, siRNA-nanoparticles accumulate into the via leaky vasculature while cellular uptake is facilitated by specific interaction between cancer cell receptors and antibodies on nanoparticles. On page 2646, J. W. Gray, Yantasee, colleagues describe design synthesis this mesoporous silica nanoparticle its application for targeted HER2-positive breast cancer.
Abstract Despite advancement in targeted therapies, treatment options for patients with acute myeloid leukemia (AML) that provide a tolerable and durable response remain elusive. We have developed CD3 bispecific antibody, QL325, targeting CLEC12A, c-type lectin protein is highly expressed on AML blasts. Normally, CLEC12A expression mostly confined to the CD34+CD38- progenitor population largely absent normal regenerating bone marrow stem cells. Our antibody configured 2 + 1 format, bivalent...
Abstract Deregulation of aspects the mitotic apparatus leads to increased genome instability, carcinogenesis and aggressive tumor behavior in human rodent model systems1. This knowledge has stimulated development inhibitors elements as anticancer agents including PLK1, CENPE, AURKB several are now being tested for efficacy clincially2-6. These trials eventual clinical use will benefit from molecular markers that predict response. In order identify such markers, we assessed quantitative...